It is possible that the administrative to immune checkpoint inhibitors might improve the outcome of CD19 CAR T-cell therapy in ALL patients who do not have a bone marrow microenvironment with T cell activation pathways32,33. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.